EP 1404705 A4 20040407 - COMPOSITIONS AND METHODS OF USING HIV VPR
Title (en)
COMPOSITIONS AND METHODS OF USING HIV VPR
Title (de)
ZUSAMMENSETZUNGEN UND VERFAHREN ZUR VERWENDUNG VON HIV VPR
Title (fr)
COMPOSITIONS ET PROCEDES D'UTILISATION D'HIV VPR
Publication
Application
Priority
- US 0110028 W 20010329
- US 19349500 P 20000331
- US 23114100 P 20000908
Abstract (en)
[origin: WO0174163A1] Methods of delivering a desired polypeptide to an individual are disclosed. The methods comprise administering to the individual an immunogenic vector comprising a nucleic acid encoding the desired polypeptide operably linked to regulatory elements in combination with one or more of Vpr protein, a functional fragment of Vpr protein, a nucleic acid encoding Vpr protein operably linked to regulatory elements, or a nucleic acid encoding fragment of Vpr protein operably linked to regulatory elements. Methods of inhibiting an undesirable immune response in an individual are disclosed. Methods for inhibiting the cellular proliferation of a tumor cell in an individual are disclosed.
IPC 1-7
IPC 8 full level
A61K 48/00 (2006.01); C07K 14/16 (2006.01); C12N 15/861 (2006.01); A61K 38/00 (2006.01)
CPC (source: EP)
A61K 48/00 (2013.01); C12N 15/86 (2013.01); A61K 38/00 (2013.01); C12N 2710/10343 (2013.01); C12N 2740/16322 (2013.01); C12N 2740/16334 (2013.01); C12N 2810/6081 (2013.01); C12N 2830/42 (2013.01)
Citation (search report)
- [XY] WU X ET AL: "TARGETING FOREIGN PROTEINS TO HUMAN IMMUNODEFICIENCY VIRUS PARTICLES VIA FUSION WITH VPR AND VPX", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 69, no. 6, 1 June 1995 (1995-06-01), pages 3389 - 3398, XP000608410, ISSN: 0022-538X
- [Y] AYYAVOO V ET AL: "HIV-1 VPR SUPPRESSES IMMUNE ACTIVATION AND APOPTOSIS THROUGH REGULATION OF NUCLEAR FACTOR KAPPAB", NATURE MEDICINE, NATURE PUBLISHING, CO, US, vol. 3, no. 10, October 1997 (1997-10-01), pages 1117 - 1123, XP002945593, ISSN: 1078-8956
- [Y] MAHALINGAM SUNDARASAMY ET AL: "HIV-1 Vpr interacts with a human 34-kDa mov34 homologue, a cellular factor linked to the G2/M phase transition of the mammalian cell cycle", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 95, no. 7, 31 March 1998 (1998-03-31), March 31, 1998, pages 3419 - 3424, XP002268991, ISSN: 0027-8424
- [A] AYYAVOO V ET AL: "Construction of attenuated HIV-1 accessory gene immunization cassettes", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 16, no. 19, 1 November 1998 (1998-11-01), pages 1872 - 1879, XP004139021, ISSN: 0264-410X
- [T] MUTHUMANI K ET AL: "Inclusion of Vpr accessory gene in a plasmid vaccine cocktail markedly reduces Nef vaccine effectiveness in vivo resulting in CD4 cell loss and increased viral loads in rhesus macaques", JOURNAL OF MEDICAL PRIMATOLOGY, vol. 31, no. 4-5, August 2002 (2002-08-01), pages 179 - 185, XP009025257, ISSN: 0047-2565
- See references of WO 0174163A1
Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR
DOCDB simple family (publication)
WO 0174163 A1 20011011; AU 4957601 A 20011015; CA 2408904 A1 20011011; EP 1404705 A1 20040407; EP 1404705 A4 20040407
DOCDB simple family (application)
US 0110028 W 20010329; AU 4957601 A 20010329; CA 2408904 A 20010329; EP 01922815 A 20010329